The historical rank and industry rank for Lixte Biotechnology Holdings's EV-to-FCF or its related term are showing as below:
LIXT'
s EV-to-FCF Range Over the Past 10 Years
Min: -37.07 Med: -6.51 Max: -1.78
Current: -1.78
During the past 13 years, the highest EV-to-FCF of Lixte Biotechnology Holdings was -1.78. The lowest was -37.07. And the median was -6.51.
LIXT's EV-to-FCF is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 8.19
vs LIXT: -1.78
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lixte Biotechnology Holdings's EV-to-FCF
For the Biotechnology subindustry, Lixte Biotechnology Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lixte Biotechnology Holdings's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lixte Biotechnology Holdings's EV-to-FCF falls into.
Lixte Biotechnology Holdings's current Enterprise Value is $6.16 Mil.
Lixte Biotechnology Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lixte Biotechnology Holdings's PE Ratio (TTM) for today is calculated as:
Lixte Biotechnology Holdings's share price for today is $1.9851.
Lixte Biotechnology Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.730.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lixte Biotechnology Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIXT has been successfully added to your 